ADAM17 and hepatocellular carcinoma: In hepatocellular carcinoma cells, miR-122 and miR-3163 upregulation can suppress ADAM17 levels, thereby inhibiting cell proliferation and enhancing sensitivity to antitumor drugs [50,51].